Meeting News

Top stories from EASD 2018

The 54th annual meeting of the European Association for the Study of Diabetes was held earlier this month, and Endocrine Today covered the latest research and themes that emerged from the meeting. The most popular topics for Healio.com/Endocrinology readers included more individualized therapies for diabetes care, reduced risk for diabetes with the weight loss therapy lorcaserin, findings from the CARMELINA cardiovascular outcomes trial and more..

Leading diabetes groups stress patient-centered care, new therapies in updated consensus report

Providers should prioritize patient-centered care for type 2 diabetes that incorporates therapy regimens tailored to specific patient goals, whereas new medications shown to reduce cardiovascular risk should be introduced earlier for high-risk patients, according to a joint consensus report published Friday by the American Diabetes Association and European Association for the Study of Diabetes.

READ

Lorcaserin reduces diabetes progression in high-risk adults with obesity, CVD

Adults with obesity, prediabetes and established cardiovascular disease randomly assigned to the serotonin receptor agonist lorcaserin were less likely to progress to overt type 2 diabetes over 3 years and more likely to revert to normoglycemia compared with similar patients assigned to placebo, according to findings published in The Lancet and presented at the European Association for the Study of Diabetes annual meeting.

READ

CARMELINA: Linagliptin safe, effective in type 2 diabetes with CVD, kidney disease

Among adults with type 2 diabetes, established cardiovascular disease and/or chronic kidney disease, the DPP-IV inhibitor linagliptin demonstrated CV safety and a neutral effect for hospitalization for heart failure and kidney outcomes vs. placebo, according to findings from the CARMELINA trial presented at the European Association for the Study of Diabetes annual meeting.

READ

Artificial pancreas improves time-in-range glucose values vs. pump therapy

A cohort of patients with type 1 diabetes, including children as young as age 6 years, treated with insulin pump therapy experienced a 10% improvement in time spent in the recommended glycemic range when randomly assigned to 12 weeks using a hybrid closed-loop insulin delivery system, according to findings published in The Lancet and presented at the European Association for the Study of Diabetes annual meeting.

READ

HARMONY: Albiglutide reduces CV risk in adults with type 2 diabetes, CVD

Adults with type 2 diabetes and atherosclerotic disease randomly assigned to the once-weekly GLP-1 receptor agonist albiglutide experienced a 22% reduction in risk for major adverse cardiac events over 1.6 years vs. similar adults assigned to placebo, according to findings from the HARMONY-Outcomes trial presented at the European Association for the Study of Diabetes annual meeting.

The 54th annual meeting of the European Association for the Study of Diabetes was held earlier this month, and Endocrine Today covered the latest research and themes that emerged from the meeting. The most popular topics for Healio.com/Endocrinology readers included more individualized therapies for diabetes care, reduced risk for diabetes with the weight loss therapy lorcaserin, findings from the CARMELINA cardiovascular outcomes trial and more..

Leading diabetes groups stress patient-centered care, new therapies in updated consensus report

Providers should prioritize patient-centered care for type 2 diabetes that incorporates therapy regimens tailored to specific patient goals, whereas new medications shown to reduce cardiovascular risk should be introduced earlier for high-risk patients, according to a joint consensus report published Friday by the American Diabetes Association and European Association for the Study of Diabetes.

READ

Lorcaserin reduces diabetes progression in high-risk adults with obesity, CVD

Adults with obesity, prediabetes and established cardiovascular disease randomly assigned to the serotonin receptor agonist lorcaserin were less likely to progress to overt type 2 diabetes over 3 years and more likely to revert to normoglycemia compared with similar patients assigned to placebo, according to findings published in The Lancet and presented at the European Association for the Study of Diabetes annual meeting.

READ

CARMELINA: Linagliptin safe, effective in type 2 diabetes with CVD, kidney disease

Among adults with type 2 diabetes, established cardiovascular disease and/or chronic kidney disease, the DPP-IV inhibitor linagliptin demonstrated CV safety and a neutral effect for hospitalization for heart failure and kidney outcomes vs. placebo, according to findings from the CARMELINA trial presented at the European Association for the Study of Diabetes annual meeting.

READ

Artificial pancreas improves time-in-range glucose values vs. pump therapy

A cohort of patients with type 1 diabetes, including children as young as age 6 years, treated with insulin pump therapy experienced a 10% improvement in time spent in the recommended glycemic range when randomly assigned to 12 weeks using a hybrid closed-loop insulin delivery system, according to findings published in The Lancet and presented at the European Association for the Study of Diabetes annual meeting.

READ

HARMONY: Albiglutide reduces CV risk in adults with type 2 diabetes, CVD

Adults with type 2 diabetes and atherosclerotic disease randomly assigned to the once-weekly GLP-1 receptor agonist albiglutide experienced a 22% reduction in risk for major adverse cardiac events over 1.6 years vs. similar adults assigned to placebo, according to findings from the HARMONY-Outcomes trial presented at the European Association for the Study of Diabetes annual meeting.

PAGE BREAK

READ

    See more from European Association for the Study of Diabetes Annual Meeting